PipelineReview.com1h
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
INCHEON, Korea and TEL AVIV, Israel I January 10, 2025 I Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced ...
PipelineReview.com1h
Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases
Ouro will leverage $120 million in funding to develop novel T cell engagers with potential to reset the immune system in patients with chronic immune-mediated ...
PipelineReview.com1h
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, MD, USA I January 10, 2025 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing ...
PipelineReview.com1h
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
UTRECHT, The Netherlands and PHILADELPHIA, PA, USA I January 10, 2025 I LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage ...
PipelineReview.com1h
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patients ...
PipelineReview.com1h
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
The primary objective of this initial clinical trial is to evaluate safety and immune responses of three different dose levels and two different vaccination schedules of ARCT-2304 vaccine. Immune ...